# US 5,707,626 A · Methods of treating HIV infection using antibodies to the U2 small nuclear ribonuclear protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,707,626 A
- Document ID: US5707626A
- Status: Granted
- Kind: A
- Application number: 08/704,170
- Filed: 1996-08-28
- Granted: 1998-01-13
- Earliest claimed: 1993-03-11
- Assignees: University of Southern California
- Inventors: Angeline Douvas; Yoshi Takehana; Glenn Ehresmann
- Web page: https://patentgrep.com/patent/US5707626A

## CPC

- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61P 31/12: Antivirals
- C07K 16/10: RNA viruses
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- C07K 16/18: against material from animals or humans
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Therapeutic strategies for the treatment of immunoinfective cluster virus infections in humans involving the use of antibodies or fragments thereof which are characteristic of autoantibodies produced by patients affected with systemic rheumatic disorders and cross-react with epitopes on an immunoinfective cluster virus. Additional therapeutic strategies include the use U1 RNA or fragments thereof to treat said viral infections.

## Claims

### Claim 1

A method of treating an individual infected with the human immunodeficiency virus type 1 (HIV-1), said method comprising administering to said HIV-1-infected individual a therapeutically effective amount of a pharmaceutical composition comprising antibodies specific for the U1 small nuclear ribonuclear protein (U1-snRNP), said U1-snRNP-specific antibodies being capable of crossreacting with HIV-1 gp120 or gp41 envelope proteins in a manner sufficient to neutralize the HIV-1 virus.